Comparative Pharmacology
Head-to-head clinical analysis: METOCURINE IODIDE versus MIVACRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METOCURINE IODIDE versus MIVACRON.
METOCURINE IODIDE vs MIVACRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive nicotinic acetylcholine receptor antagonist at the neuromuscular junction, blocking acetylcholine binding and preventing muscle contraction.
Mivacurium is a bis-benzylisoquinoline neuromuscular blocking agent that acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, leading to muscle paralysis.
Initial dose 0.2 mg/kg IV; maintenance doses of 0.1-0.15 mg/kg IV as needed for neuromuscular blockade.
0.15-0.2 mg/kg IV bolus for intubation; maintenance infusion 9-10 mcg/kg/min
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in patients with normal renal function. Prolonged in renal impairment.
Terminal elimination half-life is approximately 2-3 minutes; clinically, rapid clearance via plasma cholinesterase results in short duration.
Renal: 85-90% unchanged; biliary/fecal: <5%.
Primarily renal (approximately 80-90% as unchanged drug and metabolites) and biliary (small fraction, <20% as metabolites).
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker